NeogenFRA:NG2 -4.30%68 FCF Margin % is 5.24% as of Feb. 2026, which is 47% below its 10-year median of 9.94. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.66 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Neogen ranks better than 52.39% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Neogen's Free Cash Flow for the
three
months ended in Feb. 2026 was €9.4 Mil. Neogen's Revenue for the
three
months ended in Feb. 2026 was €178.7 Mil. Therefore, Neogen's FCF Margin % for the quarter that ended in Feb. 2026 was 5.24%.
The historical rank and industry rank for Neogen's FCF Margin % or its related term are showing as below:
FRA:NG2'
s FCF Margin % Range Over the Past 10 Years
Min: -8.24 Med: 9.94 Max: 14.78
Current: 0.68
During the past 13 years, the highest FCF Margin % of Neogen was 14.78%. The lowest was -8.24%. And the median was 9.94%.
FRA:NG2's FCF Margin % is ranked better than 52.39% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs FRA:NG2: 0.68
Neogen FCF Margin % Related Terms
Neogen FCF Margin % Historical Data
* Premium members only.
The historical data trend for Neogen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs NVCR, ESTA, AXGN: FCF Margin % Comparison
For the Medical Devices subindustry, Neogen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Neogen's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a FCF Margin % of 5.24% as of Feb. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Neogen and its competitors. This is 47% below median its historical median of 9.94. According to the industry distribution chart, Neogen ranks #388 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is Neogen's FCF Margin % too high?
Neogen's current FCF Margin % of 5.24% is 47% below median its 10-year median of 9.94. Based on the distribution chart, Neogen ranks #388 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's FCF Margin % compare to NVCR and ESTA?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #388 out of 815 companies for FCF Margin %. This puts Neogen in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Neogen and its competitors. Neogen's current FCF Margin % is 5.24%, which is 47% below median its own 10-year median of 9.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.66, compared to a current price of €7.65 — trading 28.2% below its estimated fair value. The current FCF Margin % is 5.24%, which is 47% below median its 10-year median of 9.94. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Neogen (FRA:NG2), the current FCF Margin % is 5.24% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be undervalued.
The current stock price of €7.65 is trading 28.2% below its estimated GF Value™ of €10.66.
GuruFocus considers Neogen to be Modestly Undervalued.
Key valuation signals for FRA:NG2:
FCF Margin %: 5.24% (47% below median its 10-year median of 9.94)
GF Value™: €10.66 vs. price of €7.65 (28.2% below fair value)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for FRA:NG2
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
